Get started
Author

Maozhen Gong

Observed name: Gong, Maozhen
Observed institution: AstraZeneca (United States)
ORCID: 0000-0002-1018-9404
Observed ORCID: 0000-0002-1018-9404
OpenAlex ID: A5032148285
Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2022 · Charu Aggarwal, Nabil F. Saba, et al. · Clinical Cancer Research · 51
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors
2024 · Diwakar Davar, Benedito A Carneiro, et al. · Journal for ImmunoTherapy of Cancer · 30
PDF
U-MET: Utility-Based Dose Optimization Approach for Multiple-Dose Randomized Trial Designs
2024 · Gina D’Angelo, Maozhen Gong, et al. · Statistics in Biopharmaceutical Research · 8
ARTEMIDE-Lung03: A phase 3, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic non-squamous non-small-cell lung cancer whose tumors express PD-L1.
2025 · Clarissa Mathias, Yasushi Goto, et al. · Journal of Clinical Oncology · 3
PDF
MEDI0457 Plus Durvalumab in HPV-associated HNSCC—Response
2023 · Charu Aggarwal, Maozhen Gong, et al. · Clinical Cancer Research · 2
PDF
PP01.48: ARTEMIDE-Lung03: A Phase 3, Randomized, Double-Blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-Based Chemotherapy as First-Line Treatment for Patients with Metastatic Non-Squamous Non-Small-Cell Lung Cancer Whose Tumors Express PD-L1
2026 · Christine M. Bestvina, Clarissa Mathias, et al. · Journal of Thoracic Oncology · 1
PP01.47: ARTEMIDE-Lung02: A Phase 3, Double-Blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment of Patients with Metastatic Squamous Non-Small-Cell Lung Cancer Whose Tumors Express PD-L1
2026 · Christine M. Bestvina, Shun Lu, et al. · Journal of Thoracic Oncology
Supplementary Tables S1-S3 from Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Charu Aggarwal, Nabil F. Saba, et al.
Data from Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2023 · Charu Aggarwal, Nabil F. Saba, et al.
Supplementary Figures S1-S9 from Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2023 · Charu Aggarwal, Nabil F. Saba, et al.
Supplementary Figures S1-S9 from Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2023 · Charu Aggarwal, Nabil F. Saba, et al.
Data from Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2023 · Charu Aggarwal, Nabil F. Saba, et al.
Supplementary Tables S1-S3 from Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2023 · Charu Aggarwal, Nabil F. Saba, et al.
Supplementary Tables S1-S3 from Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2023 · Charu Aggarwal, Nabil F. Saba, et al.
Works count: 15
Citation count: 95
H-index: 3
I10-index: 2
Year
Topic
Type